## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.9% below STRENGTH zone (4.0-10.0%); PEG 1.72 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Squarepoint Ops LLC Boosts Holdings in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251217T110831 | Somewhat-Bullish | Relevance: 100%
- Squarepoint Ops LLC significantly increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 724.4% in the second quarter, now owning 46,841 shares valued at $3.42 million. Other institutional investors like Ameriprise Financial Inc. and Norges Bank also made substantial changes to their HSIC holdings. Analyst ratings for Henry Schein are mixed, with an average "Hold" rating and a price target of $76.92.

**2. Traverse City Topic HENRY SCHEIN, INC. | News, Weather, Sports, Breaking News**
- Source: WPBN | 20251216T020539 | Somewhat-Bullish | Relevance: 100%
- A COVID-19 antibody test manufactured by Henry Schein is now available in Palm Beach County, Florida. The IgG/IgM test provides results in just 15 minutes, indicating whether an individual has previously been exposed to COVID-19.

**3. Top 2 Health Care Stocks That May Keep You Up At Night In December**
- Source: Benzinga | 20251216T133242 | Somewhat-Bullish | Relevance: 92%
- This article identifies two healthcare stocks, Henry Schein (HSIC) and Avidity Biosciences (RNA), that might concern investors due to their overbought status indicated by a high Relative Strength Index (RSI). Avidity Biosciences recently missed analyst consensus on quarterly losses but beat sales estimates and announced a merger agreement with Novartis, while Henry Schein received an Overweight rating from Barclays. Investors are advised to consider momentum as a key trading criterion when evaluating these stocks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.72 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.72 |
| Forward P/E | 14.6 |
| Current P/E | 15.7 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 3.9% (minimal 5-day change). Below STRENGTH zone by 0.1pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. AM_20 at 3.2% shows strong absolute momentum above own 20MA. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.90% (CS: 77) | Neutral |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.101x | Above |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.02
- **Stop Loss:** $74.02 (3.9% risk)
- **Target:** $80.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 316
- **Position Value:** $24,338.32
- **Portfolio %:** 24.34%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*